ReviewPharmaceuticals (Basel, Switzerland)2023
Liposome-Derived Nanosystems for the Treatment of Behavioral and Neurodegenerative Diseases: The Promise of Niosomes, Transfersomes, and Ethosomes for Increased Brain Drug Bioavailability.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- 20-Hydroxyecdysone-Loaded Niosomes as a Novel Nano-Therapeutic Platform for Psoriasis: In Vitro Characterization andPharmaceutics · 2026Article
- Formulation Characteristics of Solid-Dispersible Self-Emulsifying Drug Delivery Systems for Dual Drug Delivery.Pharmaceutics · 2026Article
- Effect of Loading Strategy on Methylene Blue Encapsulation in Ethosomes: A Comparative Study of Aqueous and Ethanol Phases.Methods and protocols · 2026Article
- Dual drug co-encapsulation into liposomes and liposome-derived nanosystems for improved synergistic treatment of skin diseases.Drug delivery and translational research · 2026Review
- Niosomal Encapsulation of Anti-cancer Peptides: A Revolutionary Strategy in Cancer Therapy.Current pharmaceutical biotechnology · 2026Review
- Nano-Formulated Apelin13 Reduces Cerebral Ischemia/Reperfusion Injury in Rats by Suppressing Activity of TLR4/MyD88/NF-кB Axis and Pro-inflammatory Cytokines; an Experimental Study.Archives of academic emergency medicine · 2026Article
- Breaking Through Barriers: The Transformative Potential of Nanomedicine in Overcoming Drug Delivery Challenges for Psychiatric Disorders.CNS & neurological disorders drug targets · 2026Review
- Advances in Bioactive Compounds from Plants and Their Applications in Alzheimer's Disease.Biomolecules · 2025Review
- The future of vesicular drug delivery: transferosomes in therapeutic advancement-applications, innovations and challenges.Biomedical engineering online · 2025Review
- Nanomedicine-enabled neuroprotection: therapeutic role of berberine in neurodegenerative diseases.Molecular biology reports · 2025Review
- Ethosome-Based Transdermal Drug Delivery: Its Structural Components, Preparation Techniques, and Therapeutic Applications Across Metabolic, Chronic, and Oncological Conditions.Pharmaceutics · 2025Review
- Polylactic-Co-Glycolic Acid/Alginate/Neem Oil-Reduced Graphene Oxide as a pH-Sensitive Nanocarrier for Hesperidin Drug Delivery: Antimicrobial and Acute Otitis Media Assessments.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Tailored Intranasal Albumin Caged Selegiline-α Synuclein siRNA Liposome with Improved Efficiency in Parkinson's Model.Pharmaceutics · 2025Article
- Nose-to-Brain Targeting of Resveratrol Nanoformulations.Current vascular pharmacology · 2025Review
- Nose to brain strategy coupled to nano vesicular system for natural products delivery: Focus on synaptic plasticity in Alzheimer's disease.Journal of pharmaceutical analysis · 2024Review
- Engineering Docetaxel Micelles for Enhanced Cancer Therapy Through Intermolecular Forces.Bioengineering (Basel, Switzerland) · 2024Article
- Chitosan-Tricarbocyanine-Based Nanogels Were Able to Cross the Blood-Brain Barrier Showing Its Potential as a Targeted Site Delivery Agent.Pharmaceutics · 2024Article
- The Interplay of Protein Aggregation, Genetics, and Oxidative Stress in Alzheimer's Disease: Role for Natural Antioxidants and Immunotherapeutics.Antioxidants (Basel, Switzerland) · 2024Review
- Bee Venom-Loaded Niosomes as Innovative Platforms for Cancer Treatment: Development and Therapeutical Efficacy and Safety Evaluation.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Niosomes: Composition, Formulation Techniques, and Recent Progress as Delivery Systems in Cancer Therapy.Pharmaceutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychiatric and neurodegenerative disorders are amongst the most prevalent and debilitating diseases, but current treatments either have low success rates, greatly due to the low permeability of the blood-brain barrier, and/or are connected to severe side effects. Hence, new strategies are extremely important, and here is where liposome-derived nanosystems come in. Niosomes, transfersomes, and ethosomes are nanometric vesicular structures that allow drug encapsulation, protecting them from degradation, and increasing their solubility, permeability, brain targeting, and bioavailability. This review highlighted the great potential of these nanosystems for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, bipolar disorder, anxiety, and depression. Studies regarding the encapsulation of synthetic and natural-derived molecules in these systems, for intravenous, oral, transdermal, or intranasal administration, have led to an increased brain bioavailability when compared to conventional pharmaceutical forms. Moreover, the developed formulations proved to have neuroprotective, anti-inflammatory, and antioxidant effects, including brain neurotransmitter level restoration and brain oxidative status improvement, and improved locomotor activity or enhancement of recognition and working memories in animal models. Hence, albeit being relatively new technologies, niosomes, transfersomes, and ethosomes have already proven to increase the brain bioavailability of psychoactive drugs, leading to increased effectiveness and decreased side effects, showing promise as future therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.